Global cancer statistics, CA Cancer J Clin, vol.65, pp.87-108, 2012. ,
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, pp.64-72, 2013. ,
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, vol.27, pp.3109-3116, 2009. ,
,
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, vol.25, pp.2198-2204, 2007. ,
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, vol.307, pp.1383-1393, 2012. ,
,
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08, J Clin Oncol, vol.29, pp.11-16, 2011. ,
,
,
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III ,
URL : https://hal.archives-ouvertes.fr/hal-02045524
, PETACC-8): an open-label, randomised phase 3 trial, Lancet Oncol, vol.15, pp.862-873, 2014.
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, vol.350, pp.2335-2342, 2004. ,
,
,
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, vol.360, pp.1408-1417, 2009. ,
,
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients, Br J Cancer, vol.99, pp.83-89, 2008. ,
,
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer, Br J Cancer, vol.117, pp.1777-1786, 2017. ,
The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma, Clin Colorectal Cancer, vol.9, pp.219-223, 2010. ,
Expression of insulin-like growth factor-1 receptor in human colorectal cancer, Hum Pathol, vol.30, pp.1128-1133, 1999. ,
Correlations of insulin-like growth factor I and insulin-like growth factor I receptor with the clinicopathological features and prognosis of patients with colon cancer, Jpn J Clin Oncol, vol.46, p.19, 2016. ,
Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer, Clin Cancer Res, vol.18, pp.1156-1166, 2012. ,
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer, Clin Colorectal Cancer, vol.10, pp.325-332, 2011. ,
Low levels of insulin-like growth factor type 1 receptor expression at cancer cell membrane predict liver metastasis in Dukes' C human colorectal cancers, Clin Cancer Res, vol.10, pp.8434-8441, 2004. ,
IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer, Virchows Arch, vol.443, pp.139-145, 2003. ,
,
A randomized phase II/III study of dalotuzumab in combination with cetuximab and irinotecan in chemorefractory, KRAS wild-type, metastatic colorectal cancer, J Natl Cancer Inst, vol.107, p.258, 2015. ,
Expression of IGF-1 and IGF-1R and their relation to clinicopathological factors in colorectal cancer, Anticancer Res, vol.31, pp.2541-2545, 2011. ,
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer, Oncology, vol.76, pp.42-48, 2009. ,
Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer, BMC Cancer, vol.10, p.20, 2010. ,
Gene expression profiles in normal and cancer cells, Science, vol.276, pp.1268-1272, 1997. ,
The insulin-like growth factor system and cancer, Cancer Lett, vol.195, pp.127-137, 2003. ,
Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab-or panitumumab-refractory metastatic colorectal cancer, J Clin Oncol, vol.28, pp.4240-4246, 2010. ,
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab, Target Oncol, vol.10, pp.65-76, 2015. ,
,
Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer, Clin Cancer Res, vol.20, pp.4240-4250, 2014. ,
mRNA expression of IGF-1 and IGF-1R in patients with colorectal adenocarcinoma and type 2 diabetes, Arch Med Res, vol.45, pp.318-324, 2014. ,
,
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin, Ann Oncol, vol.21, pp.772-780, 2010. ,
,
Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon ! 21 cancer patients treated with adjuvant FOLFOX chemotherapy, Clin Cancer Res, vol.17, pp.7470-7478, 2011. ,
,
Prognostic value of KRAS mutations in stage III colon cancer : post hoc analysis of the PETACC8 phase III trial dataset ,
, Ann Oncol, vol.25, pp.2378-2385, 2014.
,
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, vol.349, pp.247-257, 2003. ,
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, vol.28, pp.3219-3226, 2010. ,
,
,
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, Clin Cancer Res, vol.18, pp.6531-6541, 2012. ,
,
Role of deficient DNA mismatch repair status in patients with stage III colon cancer treated with FOLFOX adjuvant chemotherapy: a pooled analysis from 2 randomized clinical trials, JAMA Oncol, vol.4, pp.379-383, 2018. ,
Prognostic impact of deficient DNA mismatch repair and mutations in KRAS, and BRAF(V600E) in patients with lymph nodepositive colon cancer, Curr Colorectal Cancer Rep, vol.10, p.22, 2014. ,
,
, Prognostic effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, vol.14, pp.1-11, 2016.
,
Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study, Ann Oncol, vol.28, pp.1023-1031, 2017. ,
,
Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer, J Natl Cancer Inst, vol.109, 2017. ,
IGF type 1 receptor ligand binding characteristics are altered in a subgroup of children with intrauterine growth retardation, J Clin Endocrinol Metab, vol.86, pp.5516-5524, 2001. ,
Characterization of insulin-like growth factor I receptor on human erythrocytes, J Clin Endocrinol Metab, vol.61, pp.1066-1070, 1985. ,
Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival, Oncology, vol.55, pp.242-248, 1998. ,
,
Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel, Cancer, vol.94, pp.647-657, 2002. ,